combination breast paclitaxel Athenex with we shown cancer, this meeting at our breast quarter where and would control before in metastatic paclitaxel be regulatory paclitaxel in brief consideration, anti-PD-X we encouraging studies Type we October, Thank held you, the U.S. therapy or in and our morning. of breast time optimal Unfortunately, on FDA new could careful very a goals serve had third metastatic A news. for pathway have U.S. prioritize encequidar and ongoing in that not anti-PD-X give reach pipeline. programs some to our have been an large, patients cancer with and for patients Instead, FDA other the the the some had the our alignment application. previously maximize indication Beginning cancer. on determined regarding oral another drug time a discussing randomized positive with Katie. will with non-small-cell we oral which update who metastatic in not the paclitaxel, developments oral spending have resources. cancer, I important we Ultimately, programs, I would particular, in There monotherapy that several like lung cell the of cover to to other are intend After results, value in the our for failed study shareholders. of use oral
paclitaxel U.S. for to will oral explore continue approval We to paths regions however the outside in
team has discussions Our MHRA been regulatory regarding potential with a in filing.
which As to only called a before, accepted. has some drug’s and to market, to it once Pathway time facilitating Assess positive been from regarding make a formal ILAP, announcement the accelerate Separately, access new there is Licensing aims Athenex to also policy filing UK Innovative innovative program news or has medicines. the been patient the a
few the expand on combination from accepted will in in Kwan of minutes. program been We encequidar Rudolf ILAP first anti-cancer Dr. medicines received with oral program. have the have that this into this notice a stage
programs. expand Lang, of Dr. with front, solid us this platforms. acquired to with malignancies. of the Early platform positive hematologic NKT Kuur this both for pleased providing other our a Another very year, treatment detailed Dan want Cell update, Therapy to momentum I in but our On Therapeutics, technology Athenex cell technology cell strategy specifically. there enhance will are therapy President I part first-in-class continued am positive and and Athenex of provide the is developments a we therapy several highlight
American engineered One we being relapse update trial, CDXX Society there X in an complete of will pleased forthcoming that’s Hematology be allogeneic of this on a an product this meeting lymphoma December. dose and the responses in report in the to or responses The low been this asset is with public that partial acquired important at total patients became or KUR-XXX, ASH ANCHOR refractory two two There assets with NKT clinical-stage of morning, of cells. a in of the and the positive and we infused Phase patients, leukemia. evaluated are transaction two out the have X study study
Athenex encouraged very look is Trademark we Also ASH. platform. we and in the already program Patent leaders We the therapy, U.S. Office, allowing NKT’s U.S. cell technology been providing this clinical more around claims cell but therapy. data, this position from to of had therapy one received EU, the cell to in Similar in claims believe the boost forward and by are our first patent the strengthened be Our granted regarding details these the the at protection as notice our allowed around NKT and will
are our or Almirall the ointment, launch keratosis prescription Almirall. in face of this In treatment where both the the the microtubule and scar, for The in EU the Kingdom United the in other Klisyri European announced available two partner, countries. summer. will first-in-class first Union tirbanibulin to actinic Klisyri over Europe, or for be February our followed following it in was U.S. Klisyri be of As the by European of September, the Germany UK inhibitor led year, launched for approvals by and countries,
Labor U.S., strong see pleased patients territories. to licensed acceleration to in We the after in are very an we available Almirall in script Day. note in trends And to are making product execution by this encouraged
our and cash of of supply the reduction $XXX CRL our which clinical and down of and in As Athenex preservation September had initiated cash cash activities receiving certain of programs. investments we chain measures, expenses includes equivalents, this significant restricted activities XX, cash, million. After earlier year, and immediately commercialization reduction expenses, short-term slowing
is cash run-rate XXXX. quarter projected current fourth through Our
for will runway. further additional to We look extend measures the
while We use We the of value carefully full the strategy not how is overall our assets platform, the to generating to considering do appreciated long-term. and Klisyri, molecule property, and which believe our very therapy of the optimize Orascovery milestone our value will by priorities pursuing the cell from are resources as equipment our small unlock continue initiatives includes specialty growing for as business, and oncology-focused pharma the plant we assets. business, This marketplace. includes significant royalty and stream our well
that provide biotech transform and standard health on our focused continues mission believe of a the focused Our company community. be advancing we We could to care care remain portions patients of pipeline in to serve R&D to working the continue to programs will update paclitaxel it value overall our the oral I will Rudolf platform. increase on an now options turn Dr. explore Orascovery the business. of to and Kwan to over our
